ArticleFrontiers in digital health2025
DATA 5.0-Data Acquisition, Translation & Analysis-a prospective urooncological data warehouse for the 21st century.
Article in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prospective data registration is the basis of clinical oncological research. Commonly, case documentation is restricted to studies investigating a defined hypothesis. Only few institutions prospectively register all oncological patients with a reliable, sustainable and continuous follow-up infrastructure. The Department of Urology of the Heidelberg University Hospital started its prospective tumor data base in 1992. Since then, the clinical course of all oncological in-patients is continuously registered within a life-long follow-up (success rate: 93%). Associated tumor tissue is stored in the Heidelberg Biobank. In 2005, the transfer of this invaluable registry from the initial InterSystemsCache®/KRAZTUR system to a modern data warehouse was initiated. However, the transfer of existing data into a new environment proved to be technically challenging. Objective: To migrate the existing data into a modern data warehouse (DATA 5.0) while maintaining data extraction functions. Additional requirements included FHIR connectivity, big data analyses and AI applications. Methods: Together with SAP SE, DATA 5.0 was developed. Based on SAP HANA® (High Performance Analytic Appliance) it allows data registration and analysis with third party analytical tools. The project was supported by members of the SAP SE executive board and funded by the Dietmar Hopp Foundation. Results: Data Acquisition, Translation & Analysis 5.0 (DATA 5.0), a web-based tool for data registration, preservation and analysis of treatment and follow-up data, was developed to proof-of-concept stage. DATA 5.0 was then implemented into clinical practice replacing the previous system. As of today, 15,345 oncological patients and 6.7 Mio. data points are registered. Conclusion: Prospective long-term data was successfully migrated into DATA 5.0, allowing data preservation, flexibility and capabilities for future data sources. DATA 5.0, together with associated tumor tissue, is a lighthouse platform for oncological research, with capability for third party analytical tools, big data analysis and AI applications including training of digital twin models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.